Your browser doesn't support javascript.
loading
Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection.
Dai, Lianpan; Duan, Huixin; Liu, Xueyuan; Zhou, Huan; Duan, Minrun; An, Yaling; Yuan, Linfeng; Zhao, Xin; Xu, Kun; Wu, Qiang; Gao, George F.
Afiliación
  • Dai L; Institute of Microbiology of the Chinese Academy of Sciences, Beijing 100101, China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
  • Duan H; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
  • Liu X; School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Zhou H; Clinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Duan M; Yunnan University, Kunming, China.
  • An Y; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
  • Yuan L; Anhui Zhifei Longcom Biopharmaceutical, Hefei, China.
  • Zhao X; Institute of Microbiology of the Chinese Academy of Sciences, Beijing 100101, China.
  • Xu K; Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.
  • Wu Q; Clinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • Gao GF; Institute of Microbiology of the Chinese Academy of Sciences, Beijing 100101, China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China. Electronic address: gaof@im.ac.cn.
Lancet ; 402(10403): 687-689, 2023 08 26.
Article en En | MEDLINE | ID: mdl-37591291
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 / Infección Irruptiva Límite: Humans Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 / Infección Irruptiva Límite: Humans Idioma: En Revista: Lancet Año: 2023 Tipo del documento: Article País de afiliación: China